Active Biotech postpone publication of the interim report

(Thomson Reuters ONE) -



Active Biotech has decided to postpone the publication of the interim report for
January-September 2016 to November 11, 2016, after stock markets closing.
Previously communicated date was November 10, 2016.

Lund October 26, 2016

For further information, please contact
Hans Kolam, CFO
Tel. +46 46 19 20 44

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, SILC, ANYARA and
paquinimod projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00


161026_new date_Q3:
http://hugin.info/1002/R/2051112/767391.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 26.10.2016 - 08:25 Uhr
Sprache: Deutsch
News-ID 502818
Anzahl Zeichen: 1703

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 273 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech postpone publication of the interim report"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech